EXTON, Pa., Feb. 8 /PRNewswire-FirstCall/ -- Isolagen, Inc. , a biotechnology company focused on developing and commercializing emergent, novel skin and tissue rejuvenation technologies, announced today the appointment of Sandra G. Calman, M.D., AAD, to Vice President and Chief Medical Officer. In this role, Dr. Calman will guide and be responsible for the clinical development of the Company’s product portfolio and pipeline. She will report to Nicholas L. Teti, Jr., Chairman and Chief Executive Officer of Isolagen, and will serve as a member of the executive management leadership team.
“I am pleased and excited to announce the appointment of Dr. Calman to this very important position and to the Company,” said Mr. Teti. “Sandra brings a tremendous amount of clinical and industry experience, and we are highly confident that she is the right person to lead our aesthetic and therapeutic clinical development programs. In addition, Sandra’s appointment marks a critical milestone in the completion of the new Isolagen leadership team, fulfilling a key objective set out in our strategic plan.”
Dr. Calman has spent more than 15 years in various clinical roles where she successfully managed clinical research operations, leading products from development through FDA approval. She comes to Isolagen from Merck KgaA, Dey where she served as Vice President, Medical Affairs and Clinical Research and Chief Medical Officer. Previous roles include senior clinical research positions with Johnson & Johnson and Dow Pharmaceuticals where she led the clinical development program for key dermatologic and topical therapies. Dr. Calman is a Board Certified physician. She received her training at the University of Utah School of Medicine where she graduated with honors. She is an active member of the American Academy of Family Practice and the American Academy of Dermatology.
About Isolagen, Inc.
Isolagen specializes in the development and commercialization of autologous cellular therapies for soft and hard tissue regeneration. The company’s product candidates are based on its proprietary Isolagen Process. Autologous cellular therapy is the process whereby a patient’s own cells are extracted, allowed to multiply and then injected into the patient. Isolagen’s product candidates are designed to be minimally invasive and non-surgical. For additional information, please visit: http://www.isolagen.com.
All statements in this news release that are not based on historical fact are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. While management has based any forward-looking statements contained herein on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties, and other factors, many of which are outside of our control, that could cause actual results to materially differ from such statements. Such risks, uncertainties, and other factors include, but are not necessarily limited to, those set forth under Item 1A “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2005, as updated in “Item 1A. Risk Factors” in the Company’s Quarterly Reports on Form 10-Q. We operate in a highly competitive and rapidly changing environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. We disclaim any intention to, and undertake no obligation to, update or revise any forward-looking statements. Readers are also urged to carefully review and consider the other various disclosures in the Company’s Annual Report on Form 10-K for the year ended December 31, 2005, as well as other public filings with the SEC since such date.
Isolagen, Inc.
CONTACT: Charles Huiner (Investors), Isolagen, +1-484-713-6200,chuiner@isolagen.com; or Mike Beyer (Media), Sam Brown Inc.,+1-773-463-4211, beyer@sambrown.com, for Isolagen
Web site: http://www.isolagen.com/
